1991•Clinical Pharmacology & TherapeuticsRequires access
The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: A multicenter study
M. Moser, Paul A. Abraham, William M. Bennett, Norman Brachfeld, Robert P. Goodman, J. M. McKenney, John W. Hollifield, Walter M. Kirkendall, Kenneth C. Lasseter, A. S. Leon, John Lunn, Katherine Ann Reimão Miller, J Morganroth, Michael C. Ruddy, Mohinder P. Sambhi, W J Stein, Michael A. Weber, Roger Williams, Edward T. Zawada, Jacqueline DeSilva, Lynn A. Gourley, John J. Whalen
Open publisher page 10 citations
Abstract
Benazepril hydrochloride is a new angiotensin-converting enzyme inhibitor. In a multicenter study, 206 patients with mild to moderate hypertension were randomized to receive benazepril at a dose of 2, 5, 10, or 20 mg, hydrochlorothiazide, 25 mg, or placebo once daily for 4 weeks. The 20 mg dosage of benazepril lowered blood pressure to a degree equal to that of 25 mg hydrochlorothiazide: -12.2/7.7 mm Hg and -13.4/-7.5 mm Hg, respectively. Hydrochlorothiazide proved to be more effective in black subjects. At lower dosage levels of benazepril (2, 5, and 10 mg), blood pressure reduction was not significantly different from that with placebo. In those patients who failed to achieve goal diastolic blood pressure of less than 90 mm Hg with monotherapy after 4 weeks, the addition of open-label hydrochlorothiazide (25 mg/day) to benazepril, hydrochlorothiazide, or placebo produced a substantial additional decrease in blood pressure over a 2-week period. No definite adverse effects on hematologic measurements, serum biochemistry test results, or urinalyses were noted. Subjective adverse experiences were common in all groups but except in three or possibly four instances were not considered causally related to the study drug.